KLIFO, one of Denmark’s leading contract research organisations (CRO), has been sold to the Dutch private equity fund Gilde Healthcare.
KLIFO assists biotech and pharmaceutical companies in connection with the development of new products in all stages from clinical research to public authority approval. The company was formed in 1994 and, since the formation, it has opened offices in several countries, including Sweden, Germany and the Netherlands.
“In the past few years, KLIFO has delivered significant growth, and now is the right time for the company to take the next step on its journey. This strategic investment, along with the support of Gilde’s experienced healthcare professionals, will help sustain our growth ambitions and enable KLIFO to realise its full potential, creating solutions and value for our clients,” says CEO of KLIFO Alejandra Mørk.
Rafael Natanek, Partner at Gilde Healthcare, adds: “We see pharma outsourcing as an attractive segment currently going through a consolidation wave. We are impressed by KLIFO’s highly skilled employees, rapid growth and reputation for competence, flexibility and offering integrated solutions. We look forward working with the management team to help them build on their success, and help the company in its next phase of growth.“
Accura advised the sellers of KLIFO in connection with the transaction.